FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

  • V. Subbiah
  • , N. O. Iannotti
  • , M. Gutierrez
  • , D. C. Smith
  • , L. Féliz
  • , C. F. Lihou
  • , C. Tian
  • , I. M. Silverman
  • , T. Ji
  • , M. Saleh

Research output: Contribution to journal › Article › peer-review

155 Citations (Scopus)

Fingerprint

Dive into the research topics of 'FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science